In a phase 2 double-blind trial, psilocybin, a synthetic compound found in psychedelic mushrooms, was investigated for its potential in treating treatment-resistant depression. Adults with this condition were randomly assigned to receive a single dose of psilocybin at 25 mg, 10 mg, or a 1 mg control, alongside psychological support. The study found that the 25 mg dose significantly reduced depression scores over three weeks compared to the 1 mg dose. However, it was associated with adverse effects, including headaches, nausea, and dizziness. Further research, including larger and longer trials comparing psilocybin with existing treatments, is needed to assess its efficacy and safety for treatment-resistant depression.
Related Posts
When Perception Doesn’t Match Reality?
Introduction: You pour your heart and soul into your work, fueled by the belief that you’re a rock star. But then, reality comes crashing down in the form of feedback that doesn’t align with your self-image. Maybe your project fell flat, or your leadership style left colleagues bruised. Ouch! It’s a moment that can shatter […]
The Networking Paradox: Why Building Relationships Can Backfire ?
The Networking Paradox The common belief is that networking is crucial for career advancement. However, new studies indicate that the type of network you create may actually hinder your performance depending on your cognitive style. A study published in the Academy of Management Journal discovered that individuals who are more adaptable and focus on practical […]
New Brain Biopsy Technologies Could Improve Accuracy and Efficiency
Future advances in augmented reality and artificial intelligence could enhance both preoperative planning of the biopsy trajectory and its intraoperative real-time viewing. This could lead to more precise and accurate brain biopsies, with fewer complications. Technologies like 5-ALA for better diagnosis, ICG fluorescence to avoid hurting blood vessels, and robotic systems are already used […]